Keyphrases
Advanced Treatment
28%
Atezolizumab
28%
Breast Cancer Progression
28%
C-type Lectin-like Receptor 2
35%
Chemotherapy Resistance
28%
Circulating Tumor DNA (ctDNA)
28%
Defactinib
28%
Dendritic Cells
36%
DNA Profiling
28%
Dose Escalation
28%
Dose Expansion
28%
Fibrosis
28%
Gemcitabine
28%
Glomerular Filtration Barrier
28%
Hemostasis
28%
High Endothelial Venules
28%
Immune Checkpoint Blockade
28%
Immune Checkpoint Inhibitors
28%
Immune Response
33%
Immune Surveillance
59%
Lenalidomide
28%
Lung Cancer
61%
Lymphangiogenesis
28%
Lymphatic Endothelial Cells
35%
Lymphaticovenous
28%
Lymphatics
28%
Mouse Kidney
28%
Mucin-type O-glycan
57%
Non-small Cell Lung Cancer (NSCLC)
47%
O-glycan
100%
O-glycosylation
28%
Pancreatic Cancer
57%
Pancreatic Ductal Adenocarcinoma
42%
Paucity
28%
Pembrolizumab
28%
Platelets
85%
Podoplanin
57%
Previously Treated
28%
Ramucirumab
28%
Recent Advances
28%
Small Cell Lung Cancer
38%
Stable Expression
28%
Stage I Lung Cancer
28%
Stage IV Non-small Cell Lung Cancer
28%
Targetable Alterations
28%
Treatment Refractory
28%
Tumor Progression
28%
Tumor-associated
28%
Vascular Integrity
33%
Vascular Network
28%
Biochemistry, Genetics and Molecular Biology
C-Type Lectin
10%
Cancer Growth Factor
7%
Cancer Model
10%
Cell Infiltration
7%
Chemokine
7%
Circulating Tumor DNA
28%
CLEC1B
5%
Dendritic Cell
14%
DNA Profiling
28%
Fibroblast
7%
Gelatinase A
9%
Glomerular Filtration Barrier
28%
Glycoprotein
13%
Glycosylation
46%
Growth Factor Receptor
7%
Immune Checkpoints
28%
Immune Response
40%
Immunosurveillance
34%
Lymphocyte
17%
Lymphocyte Homing
5%
Macrophage
14%
MMP2
9%
Mucin
60%
N-Acetylgalactosamine
7%
Platelet
57%
Podocyte
19%
Polysaccharide
92%
Regulatory T Cell
7%
Serine
7%
Sphingosine-1-Phosphate
17%
Stable Expression
28%
T Cell
28%
Threonine
7%
Thrombocyte Activation
5%
VE-cadherin
11%
Wild Type
15%
Medicine and Dentistry
Atezolizumab
28%
Biopsy Technique
7%
Blood Stasis
28%
Cell Signaling Pathway
5%
Circulating Tumor DNA
28%
Diseases
8%
High Endothelial Venules
28%
Immune Checkpoint Inhibitor
28%
Lenalidomide
28%
Lung Cancer
34%
Lymph Duct
33%
Lymph Node
9%
Lymphangiogenesis
28%
Lymphatic System
6%
Lymphocyte
7%
Macrophage
9%
Malignant Neoplasm
12%
Mantle Cell Lymphoma
28%
Neoplasm
13%
Non Small Cell Lung Cancer
28%
Overall Survival
14%
Platelet
57%
Podoplanin
28%
Progression Free Survival
9%
Ramucirumab
28%
Receptor
11%
Recurrent Disease
5%
Small Cell Lung Cancer
61%
Sphingosine 1 Phosphate
7%
Thoracic Duct
8%
Thrombocyte Aggregation
8%
Thrombus
8%
Tumor Microenvironment
5%
Tumor Progression
9%
Vascular Network
16%